



Two S Pharma Sole Co.,Ltd



MARKET STUDY – DISTRIBUTION by CONTINENTS

SERUM U – Serum UNIVERSAL – DENGUE RELEASE & SUPPORT


DENGUE FEVER 2021/ 2032

DECONOP – Dengue Economic Protection/ MARKET PROJECTION

DECOLOP – Dengue Ecologic Protection/ MARKET PROJECTION

CONTENT

LARGE SCALE COMMERCIAL DISTRIBUTION	1
YOUR DISTRIBUTION ZONE:	
<i>AMERICA GRAND NORTH</i>	5
<i>SOUTH AMERICA</i>	5
<i>NORTH AMERICA</i>	5
<i>NORTH EAST ASIA</i>	15
<i>EAST ASIA</i>	15
<i>SOUTH EAST ASIA – CONTINENTAL</i>	15
<i>SOUTH EAST ASIA – ISLANDS</i>	20
<i>CENTRAL ASIA</i>	20
<i>INDIAN OCEAN & the HIMALAYA'S</i>	20
<i>EASTERN AFRICA</i>	25
<i>SOUTH AFRICA</i>	25
<i>NORTH AFRICA</i>	25
<i>MEDITERANEAN</i>	30
<i>SOUTH EUROPE</i>	30
<i>NORTH EUROPE</i>	30
<i>ATLANTIC – NORTH & SOUTH</i>	35
<i>AUSTRALIA – NEW ZEALAND – TASMANIA</i>	35
<i>OCEANIA – PACIFIC AUSTRAL – PACIFIC NORTH</i>	35
<i>The Caribbean</i>	40
<i>Panama & Suez Canal REGION</i>	45
ANTARCTICA – INTERNATIONAL BASE CAMP	50



Proposal for large scale distribution of SERUM U.


This proposal assess both the market demand and research for the distribution of the SERUM Universal or SERUM U for the use in mosquitoes transmittable disease and bio-ecospheric illness. This proposal is updated #2019, #2020 and this sample is the latest edition with relevance to the ongoing surge of Microbial, Viral and Chemical Outbreaks of Natural and Human born illnesses & diseases with a planetary impact on population disregarding societal status.

This proposal support the conclusion that the use of serum for the support and recovery of multiple Blood transmittable diseases and illnesses is a reliable and effective way to approach any Endemi/Epidemi/Pandemi cycles pertaining to strong and favorable attributes such as conservancy viability, production capacity or distribution facility.

DENGUE Fever. Dengue and related conditions have affected directly and indirectly over 400 million people worldwide in 2020, SERUM U, an Isotonic Solution or Bios Serum developed under 2SPHARMA license and manufactured by FACTORY UNIT No3 Lao PDR was successfully trailed and is under the exclusive distribution of 2SPHARMA Sole Co Ltd, the result is a capacity to address the demanding societal low to under-class market worldwide effectively.

The commercial segment of this proposal was made possible by the participation of numerous referenced research institutes, biology labs and individuals who are facing the real life issues and systematic problems that Blood illnesses & diseases weight on population. The Humanitarian and Community distribution network is in permanent demand for support products, a true situation only aggravated with the SARS2 – COVID19 Outbreak but also valid for Ebola, Zinka, Malaria and in general every Blood illnesses & diseases. Humanity is entering an epoch made of new challenges, prevention, support and treatment must be adjusted in order to maintain cohesion.

This proposal provide an insight on this market segment.







Business development and commercial perspectives.

The demand for Biologic Serum have been in constant progression in any types of Serum. The period 2016-2019 have seen a surge in demands worldwide and the commercial prospects are evolving toward wider markets.

Variability is the new norm, adaptative solution the new answer. The constant growth in revenues and regular cycle of use of these revenues for R&D in the Serum industry is now showing clear and satisfactory results.

Globalization effect is clear and every region can be considered as marketable for SERUM U. The market demand is growing permanently with a the 'push' period 2016-2027 directly related to Natural Climatic Changes, Human activities & Heliospheric events.

SERUM U was developed and trailed in the natural (rural) and human (urban) environment favorable for Dengue Endemi in South East Asia, thus taking in consideration both standardized development for manufacturing and problematic and emergence and real time application to the population.



DSS – Dengue Shock Syndrome, SERUM U – a responsible alternative.

Dengue is a serious public health problem worldwide. Dengue shock syndrome (DSS), the severe form of dengue fever, can cause death within 12–24 hours if appropriate treatment is not promptly administered.

For patients with DSS and the 30% of non-shocked dengue patients who require intravenous fluid therapy, a range of solutions is available for plasma volume support. Crystalloid solutions, such as normal 0.9% saline or Ringer's lactate, are the ones most commonly used. In severe cases, colloid solutions may be administered for their greater osmotic effect, although they carry a greater risk of adverse events.

This paper summarizes the key clinical data, comparing fluid regimens in children with severe dengue, and concludes that the majority of patients with DSS can be treated successfully with isotonic crystalloid solutions.


If a colloid is thought necessary, a medium-molecular-weight preparation that combines good initial plasma volume support with good intravascular persistence and an acceptable side-effect profile is optimal. Further research should aim to determine whether there are benefits to early treatment with colloids, and which colloid solution is most effective for resuscitation of DSS patients.

From a Patient perspective, the best available solution need to be affordable, effective and available. An ideal intravenous fluid for patients with dengue is one that is isotonic. However, even isotonic crystalloid solutions have their limitations and to understand the limitations of these solutions to avoid complications have been one of SERUM U development focus.

For example, immunodeficient cases supporting large volumes of SERUM U have help to identify this solution as an efficient and universal support. It is advisable to change to other alternatives such as SERUM U which should be considered in dengue patients with significant liver involvement or failure and in patients with impaired cardio-vascular metabolism. An overall market size of 2.7 billion individuals worldwide.


SERUM UNIVERSEL DENGUE PROTECTION - STOCK MINIMA 2021 2022						
CONTINENT	AFRICA	CONTINENTAL ASIA	INDIA & INDIAN OCEAN	ASIAN ISLANDS	AMERICAS & CARIBBEAN	
CONSTANT STORE AND RESERVE	21 000 000/500ML	12 000 000/500ML	23 000 000/500ML	9 000 000/500ML	24 000 000/500ML	
TIME OF CONSERVENCY	60MONTH	60MONTH	60MONTH	60MONTH	60MONTH	
FREQUENCY OF USE/12MONTH OR 1 SEASON	100%	100%	100%	100%	100%	
CONSTANT MINIMUM STOCK REQUIREMENT	2 100 000/500ML/YEAR	1 200 000/500ML/YEAR	2 300 000/500ML/YEAR	900 000/500ML/YEAR	2 400 000/500ML/YEAR	

*YOUR MARKET/ 2SPHARMA FOCUS ON DISTRIBUTION WITH A CONTINENTAL APPROACH THUS
TAKING IN CONSIDERATION THE CONTINENTAL CLIMATICS IN ORDER TO PROVIDE WITH AN
ACCURATE AND REALISTIC SERVICE.*




MARKET DEMAND – Population/ 3 TO 4 million direct and non direct affected per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of Aedes mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in about half of all North Americas Countries.




500MI PATCH

TOTAL MARKET CAPACITY PER YEAR/ 1.4m




MARKET DEMAND – Population/ 3 TO 4 million direct and non direct affected per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of Aedes mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in about half of all Asia Nations.




500MI PATCH

TOTAL MARKET CAPACITY PER YEAR/ 2.1m




MARKET DEMAND – Population/ 2.5 TO 3 million direct and non direct affected per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of Aedes mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in about half of all Asian Island Nations & Countries.




TOTAL MARKET CAPACITY PER YEAR/ 1.8m




MARKET DEMAND – Population/ 5 TO 6 million direct and non direct affected per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of *Aedes* mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in about half of all African Countries.




500MI PATCH

TOTAL MARKET CAPACITY PER YEAR/ 2.6m



MARKET DEMAND – Population/ 2 TO 4 million direct and non direct affected per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of Aedes mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in about half of all Mediterranean Countries.




500MI PATCH

TOTAL MARKET CAPACITY PER YEAR/ 1.3m




MARKET DEMAND – 1 TO 2 million per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of *Aedes* mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas. Oceans favor mosquitoes migration and *Aedes* is present in all Countries and nation with natural border to Ocean's.




TOTAL MARKET CAPACITY PER YEAR/ .7m

large human trans-migration platform/



MARKET DEMAND – 2 TO 3 million per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of Aedes mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in all the Caribbean's a large human and mosquitoes migration platform.



500MI PATCH


TOTAL MARKET CAPACITY PER YEAR/ 1.7m

large merchandize trans-continental/trans-oceanic media zone/
constant trans-continental/trans-oceanic human presence & exchange/
natural foyer/
High risk zone of biological born virus/germ/microbe trans-migration/



MARKET DEMAND – 2 TO 5 million per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of *Aedes* mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas and are present in both Trans oceanographic passway Suez Canal and the Panama Canal.




500MI PATCH

TOTAL MARKET CAPACITY PER YEAR/ 2m



MARKET DEMAND – 200K per YEAR

Dengue fever is the most frequently occurring arthropod-borne viral disease in the world. Dengue is transmitted through the bite of *Aedes* mosquito vectors (*Aedes aegypti* and less commonly, *Aedes albopictus* or *Aedes polynesiensis*), which are distributed widely in subtropical and tropical areas the passway for all cargo and personels working on the Antarctic Continent.



TOTAL MARKET CAPACITY PER YEAR/ .1m

TWOSPHARMA – 2SPHARMA

Introduction.

In view of societal disruption due to a raise in infectious disease, and in consideration with the buying power minimum average of 2 third of the planet population, 2SPHARMA intend to promote a range of products and solutions directly sourced from the Lao PDR for the overseas markets.

2SPHARMA has an experience record of identifying and efficiently acting on Dengue cases in the habitable zone known as the Equatorial belt, which is now under the pressure of Regional weather shift due to Climate Change widening the reproduction of Mosquitoes colonies exposing further more Society to outbreak of transmissible disease.

This document is to propose and implement a prevention mechanism for the Economic safety of Dengue Fever impact DECONOP (Dengue Economic Protection) and to address the need for Dengue Ecological prevention DECOLOP (Dengue Ecologic Protection) during the ongoing Climatic, Geostatic and Epidemiologic disruption.

2SPHARMA with the supports of its ecosystem of partners such as PDC PHARMACEUTICAL FACTORY³ Lao PDR, DEEPBLUE SMARTHOUSE, and active partners in Africa, India, Mid East, South & Central America and Oceania, propose turn key solution from the diversified and alternative community worldwide. We are sincerely looking forward to work with you. The proposal include 3 main services:

- 1/ basic needs/ access to preventive and supportive products (Serum, Dietetic,...).
- 2/ basic services/ the development of local task force to tackle salubrity issues.
- 3/ infrastructures/ transportable field hospital, pharmaceutical factoring.

(see presentation attachment in annexes)

PREVENTION, the key to Economic and Ecologic Protection.

Pricing/

All pricing are made in accordance with the buying power of developing Nation, thus aligning with Continental Africa, South America and Asia actual and real economic environment.

(sample price list of Goods & Services attach)

Distribution/

Fortunately, the planetary logistic system have grown to such extends that medical products and medical equipment can travel across the globe and be delivered in the best timing and best conditioning facilitating access to remote location.

(consult 2SPHARMA)

Sustainability/

Of course continuity is an issue, 2SPHARMA is able to follow up and provide with both, the distribution of it's basic goods and services as well as promoting local R&D focus on primordial solution to answer future basic needs.

(2SPHARMA turnkey solutions)

Production/

Reliable manufacturer have been identified over the year, and 2SPHARMA is able to produce quality products and goods following international standard quality and protocol.

(2SPHARMA quality/efficiency)

Accessibility

The main concern and relevant problematic to address "it is not because goods and products exist that the general population have access to it", from environmental cause to political outcomes, 2SPHARMA intend to promote a fair and sustainable access to its Goods, Products and Services.

(consult 2SPHARMA)

2SPHARMA DIETARY GOODS & DIETETIC PRODUCTS

Artisanal processed goods for Dengue fever prevention/ Immunity boosting foods.

Citrus

Citrus foods are rich in vitamin C which helps in building strong immunity. Vitamin C helps in the production of white blood cells which are the disease-fighting cells of the body. These foods are also loaded with antioxidants which protect the body from damage from free radicals.

(citrus foods supplements such as energy bars production can be augmented according to demand.)



Garlic

Garlic adds a strong taste to the food. It is a part of almost every Indian kitchen. Garlic can also contribute to better immunity. It can help in fighting infections. Garlic has antibacterial and anti-fungal properties as well. The presence of sulfur in garlic contributes to better immunity.

(Garlic can add flavor as well as improve immunity, Lao PDR can source with multiple variety of Artisanal process Garlic product, Dry, Fried, Powder, Jam,...)



Ginger

Ginger has a strong flavor which is used to add flavor to teas. Ginger is also an immunity-boosting food. Ginger is very helpful in treating sore throat, inflammation, nausea and other symptoms of dengue fever, 2SPHARMA is sourcing Ginger Artisanal made product from Lao PDR.

(Ginger is widely use in Lao PDR, and goods such as Ginger Sweet, Ginger Tea, Dry Ginger are Artisanal produce and suitable for exports).



(ARTISANAL PROCESSED CONSUMER GOODS. The demand for consumer goods Artisanal process following modern environment of safety protocols is growing worldwide.)

2SPHARMA INTRA & INFRA SOLUTIONS *(non exhaustive list)*

INSECTIFUGES – Artisanal production



SERUM Universal – SERUMU/ Dengue, hemorrhagic fever.

(see presentation page)

SERUM Chirurgical – SERUMC/ Surgery, post natal complication.

(see presentation page)

DIETETIC – Artisanal goods/ Energy bars & Natural booster.

EX:

Citrus Energy bars



Papaya Leave concentrate



INFRASTRUCTURE – Transportable/Modulable Field Hospital/ 10 to 500 Beds capacity.

The proposal includes a turn key solution/ from 10 beds to 500 beds// Fully transportable and erectable at will. This solution provide with a better cost/efficiency than container or tents, its adaptability to any terrain is out-competing traditional hospital structures.



LAYOUT AND EQUIPMENT LIST					
Code	Department	Unit	Code	Department	Unit
E01	Operating Room	1	C02	Pharmacy	1
E02	ICU	1	C03	Radiology	1
TL01	Patient Ward	3	C04	Toilet and Bath Unit	5
TL02	Refectory	2	C05	Storage and Transport	5
TL03	Staff Ward	2	C06	Power Supply	1
T02	Patient Transfer	1	C07	Fresh Water and Waste Water Unit	1
T03	Triage	1	C08	Laundry	1
T04	Doctor Room	1	C09	Kitchen Unit (Cooking)	1
C01	Laboratory	1	C10	Sterilization	1

(for inquiries see contact page)

PRICING/ *(average/TBC)*

SERUMU

SERUM U – DENGUE
WITH PERFUSION KIT/
CIF WORLDWIDE – BOX OF 20 PATCH/500ml
\$180.00 equivalent to 1 OR 2 INDIVIDUAL TREATMENT/

DIETETIC GOODS

CONCENTRATE/SUPPLEMENTS/ENERGY BARS
CIF WORLDWIDE –
CONCENTRATE/from \$100/L
SUPPLEMENTS/from \$100/Kg
ENERGY BARS/from \$1000/100Kg

INSECTIFUGES

INCENTS/OILS/REPELANT
CIF WORLDWIDE – from:
\$100/10Kg

INFRASTRUCTURES

10 to 500 BEDS TURN KEY
CIF WORLD WIDE – 2 options/

Off Grid –
Ex: 50 beds \$2.8m

On Grid –
Ex: 50 beds \$2.4m

(free consultation)

2SPHARMA IS READY TO ANSWER YOUR DEMANDS.

DETAILED PROPOSAL ON REQUESTS/

SCHEDULE PAYMENT – LC/

WE SERVICE PRIVATE & INSTITUTIONAL ORGANIZATION/

2SPHARMA EXPORT CIF – WORLDWIDE/

CONTACT AND INQUIRES:

Licence Two S Pharma Sole Ltd.Com No 802 / VTE – Laos PDR

INTERNATIONAL EXPORT MARKET/
DAVID OSTIN +856 20 5677 2916 (MOBILE & WHATSAPP)
BY EMAIL / daveostin@yahoo.co.uk
ZOOM / davidostin@yahoo.co.uk